Warner Chilcott files patent infringement suit against Watson Pharmaceuticals

By Lisa Kerner

Charlotte, N.C., July 31 - Warner Chilcott Co. said it has filed suit against Watson Laboratories, Inc. and Watson Pharmaceuticals, Inc. in the U.S. District Court for the District of New Jersey alleging infringement of Warner's patent that protects Loestrin 24 Fe.

The lawsuit is in response to Watson's Abbreviated New Drug Application filed with the Food and Drug Administration to market a generic version of Loestrin 24 Fe prior to the expiration of Warner's patent.

Located in Millbrook, Northern Ireland, Warner is a specialty pharmaceutical company focused on branded prescription products for women's health care and dermatology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.